Inhibition of tumor angiogenesis in lung cancer by T4 phage surface displaying mVEGFR2 vaccine

Vaccine

Volumn 29, Issue 34, 2011, Pages 5802-5811

  Ren, Shunxiang ^a   FengYu, ^a   Zuo, Shuguang ^d   Zhao, Minyi ^b   Wang, Xiaobin ^c   Wang, Xicai ^d   Chen, Yan ^d   Wu, Zhiping ^d   Ren, Zhaojun ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Expression BioSciences LLC   (United States)

^c SOUTHEAST UNIVERSITY   (China)

^d KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Bacteriophage T4; Cancer therapy; Self immunization; VEGFR2

Indexed keywords

CD31 ANTIGEN; ENDOGLIN; IMMUNOGLOBULIN; RECOMBINANT VACCINE; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIOPHAGE T4; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HISTOPATHOLOGY; IN VITRO STUDY; LEWIS CARCINOMA; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURFACE PROPERTY; WESTERN BLOTTING;

ADOPTIVE TRANSFER; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; BACTERIOPHAGE T4; CANCER VACCINES; CARCINOMA, LEWIS LUNG; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; IMMUNOTHERAPY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79960559171     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.051     Document Type: Article

References (39)

1. Lu D., Jimenez X., Zhang H., Bohlen P., Witte L., Zhu Z. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer 2002, 97:393-399.
2. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002, 20:4368-4380.
3. Millauer B., Wizigmann-Voos S., Schnurch H., Martinez R., Moller N.P., Risau W., et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993, 72:835-846.
4. Zeng H., Dvorak H.F., Mukhopadhyay D. Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J Biol Chem 2001, 276:26969-26979.
5. Shinkai A., Ito M., Anazawa H., Yamaguchi S., Shitara K., Shibuya M. Mapping of the sites involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor. J Biol Chem 1998, 273:31283-31288.
6. Dias S., Hattori K., Zhu Z., Heissig B., Choy M., Lane W., et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000, 106:511-521.
7. Ferrajoli A., Manshouri T., Estrov Z., Keating M.J., O'Brien S., Lerner S., et al. High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res 2001, 7:795-799.
8. Heiser A., Coleman D., Dannull J., Yancey D., Maurice M.A., Lallas C.D., et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002, 109:409-417.
9. Ramirez B.S., Pestana E.S., Hidalgo G.G., Garcia T.H., Rodriguez R.P., Ullrich A., et al. Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant. Int J Cancer 2006, 119:2190-2199.
10. Zhang Y., Ma B., Zhou Y., Zhang M., Qiu X., Sui Y., et al. Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells. Breast Cancer Res Treat 2007, 105:277-286.
11. Koido S., Hara E., Homma S., Torii A., Toyama Y., Kawahara H., et al. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin Cancer Res 2005, 11:7891-7900.
12. Wei Y.Q., Wang Q.R., Zhao X., Yang L., Tian L., Lu Y., et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000, 6:1160-1166.
13. Hu B., Wei Y., Tian L., Zhao X., Lu Y., Wu Y., et al. Active antitumor immunity elicited by vaccine based on recombinant form of epidermal growth factor receptor. J Immunother 2005, 28:236-244.
14. Ren Z.J., Baumann R.G., Black L.W. Cloning of linear DNAs in vivo by overexpressed T4 DNA ligase: construction of a T4 phage hoc gene display vector. Gene 1997, 195:303-311.
15. Ren ZBlack L.W. Phage T4 SOC and HOC display of biologically active, full-length proteins on the viral capsid. Gene 1998, 215:439-444.
16. Ren Z.J., Lewis G.K., Wingfield P.T., Locke E.G., Steven A.C., Black L.W. Phage display of intact domains at high copy number: a system based on SOC, the small outer capsid protein of bacteriophage T4. Protein Sci 1996, 5:1833-1843.
17. Ren S.X., Ren Z.J., Zhao M.Y., Wang X.B., Zuo S.G., Yu F. Antitumor activity of endogenous mFlt4 displayed on a T4 phage nanoparticle surface. Acta Pharmacol Sin 2009, 30:637-645.
18. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79:315-328.
19. Fichtner ITanneberger S. Preoperative (neoadjuvant) chemotherapy in the murine Lewis lung carcinoma and possible implications for clinical use. Anticancer Res 1987, 7:227-233.
20. Himmele J.C., Rabenhorst B., Werner D. Inhibition of Lewis lung tumor growth and metastasis by Ehrlich ascites tumor growing in the same host. J Cancer Res Clin Oncol 1986, 111:160-165.
21. Gorelik E., Segal S., Feldman M. Control of lung metastasis progression in mice: role of growth kinetics of 3LL Lewis lung carcinoma and host immune reactivity. J Natl Cancer Inst 1980, 65:1257-1264.
22. Czerkinsky C.C., Nilsson L.A., Nygren H., Ouchterlony O., Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 1983, 65:109-121.
23. Lu N., Gao Y., Ling Y., Chen Y., Yang Y., Gu H.Y., et al. Wogonin suppresses tumor growth in vivo and VEGF-induced angiogenesis through inhibiting tyrosine phosphorylation of VEGFR2. Life Sci 2008, 82:956-963.
24. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995, 36:169-180.
25. Liu J.Y., Wei Y.Q., Yang L., Zhao X., Tian L., Hou J.M., et al. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 2003, 102:1815-1823.
26. Constant SLBottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 1997, 15:297-322.
27. Horton H.M., Anderson D., Hernandez P., Barnhart K.M., Norman J.A., Parker S.E. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha. Proc Natl Acad Sci U S A 1999, 96:1553-1558.
28. Wei Y., Zhao X., Kariya Y., Fukata H., Teshigawara K., Uchida A. Induction of autologous tumor killing by heat treatment of fresh human tumor cells: involvement of gamma delta T cells and heat shock protein 70. Cancer Res 1996, 56:1104-1110.
29. Urban JLSchreiber H. Tumor antigens. Annu Rev Immunol 1992, 10:617-644.
30. Crombet T., Torres O., Neninger E., Catala M., Rodriguez N., Ramos M., et al. clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor. Cancer Biother Radiopharm 2001, 16:93-102.
31. Saltz L.B., Meropol N.J., Loehrer P.J., Needle M.N., Kopit J., Mayer R.J., et al. trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22:1201-1208.
32. Janne P.A., Gurubhagavatula S., Yeap B.Y., Lucca J., Ostler P., Skarin A.T., et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839 " Iressa" ) on an expanded access study. Lung Cancer 2004, 44:221-230.
33. Ren Z.J., Tian C.J., Zhu Q.S., Zhao M.Y., Xin A.G., Nie W.X., et al. Orally delivered foot-and-mouth disease virus capsid protomer vaccine displayed on T4 bacteriophage surface: 100% protection from potency challenge in mice. Vaccine 2008, 26:1471-1481.
34. Wu J., Tu C., Yu X., Zhang M., Zhang N., Zhao M., et al. Bacteriophage T4 nanoparticle capsid surface SOC and HOC bipartite display with enhanced classical swine fever virus immunogenicity: a powerful immunological approach. J Virol Methods 2007, 139:50-60.
35. Schwartz R.H. T cell clonal anergy. Curr Opin Immunol 1997, 9:351-357.
36. Coutinho A., Hori S., Carvalho T., Caramalho I., Demengeot J. Regulatory T cells: the physiology of autoreactivity in dominant tolerance and " quality control" of immune responses. Immunol Rev 2001, 182:89-98.
37. Bruttin ABrussow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother 2005, 49:2874-2878.
38. Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997, 18:263-266.
39. Hung K., Hayashi R., Lafond-Walker A., Lowenstein C., Pardoll D., Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998, 188:2357-2368.